Menu
Back to Journals » OncoTargets and Therapy » Volume 12
Original Research
GADD45α-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes NSCLC cells to cisplatin, resveratrol, and radiation regardless of p53 status
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 4,230 | Dovepress* | 3,930+ | 779 | 4,709 | |
| PubMed Central* | 300 | 89 | 389 | ||
| Totals | 4,230 | 868 | 5,098 | ||
| *Since 26 April 2019 | |||||
View citations on PubMed Central and Google Scholar